Cardiac Amyloidosis: Diagnosis and Treatment

Written by Medicover Team and Medically Reviewed by Dr Pabba Anish , Cardiologists

Causes
Find a Doctor
Diagnosis
Treatment
FAQs
Book an Appointment

1. Causes 2. Find a Doctor 3. Diagnosis 4. Treatment 5. FAQs

Cardiac amyloidosis is an often misunderstood and overlooked condition that can have profound implications on heart health. This disorder is characterized by the deposition of amyloid proteins in the cardiac tissue, leading to severe consequences for heart function.

As the medical community continues to enhance its understanding of this condition, it becomes imperative to disseminate knowledge about its symptoms, causes, diagnosis, and treatment options.

What are the Symptoms of Cardiac Amyloidosis?

The clinical presentation of cardiac amyloidosis can vary significantly, often mimicking other cardiovascular disorders. However, specific hallmark symptoms may suggest its presence:

Common Symptoms

Heart Failure: Patients often exhibit symptoms of heart failure, including shortness of breath, fatigue, and fluid retention, primarily due to the heart's reduced pumping efficiency.
Arrhythmias: Irregular heartbeats, such as atrial fibrillation, can occur as the amyloid deposits disrupt the normal electrical conduction pathways.
Orthostatic Hypotension: A drop in blood pressure upon standing, leading to dizziness or fainting, may be observed due to autonomic nerve involvement.
Chest Pain: Although less common, some patients may experience chest pain resembling angina.

Other Manifestations

Apart from cardiac symptoms, systemic manifestations may include:

Peripheral Neuropathy: Tingling or numbness in the extremities.
Carpal Tunnel Syndrome: Compression of the median nerve in the wrist.
Macroglossia: An enlarged tongue, particularly in AL amyloidosis.

What are the Causes of Cardiac Amyloidosis?

The etiology of cardiac amyloidosis can be traced back to several underlying conditions:

Light Chain (AL) Amyloidosis: This form is caused by the overproduction of light chain proteins, typically associated with plasma cell disorders such as multiple myeloma. The proteins misfold and aggregate, forming amyloid deposits in various organs, including the heart.
Transthyretin (ATTR) Amyloidosis: ATTR can be hereditary or acquired. The hereditary form results from genetic mutations in the transthyretin protein, whereas the wild-type form results from age-related changes.
Secondary (AA) Amyloidosis: This type is associated with chronic inflammatory conditions and results from the deposition of serum amyloid A protein.

Understanding the specific cause of amyloidosis is crucial for tailoring appropriate treatment strategies.

When to See a Doctor for Cardiac Amyloidosis?

Seek medical attention if you:

Experience persistent shortness of breath, fatigue, or reduced exercise tolerance.
Notice swelling in your legs, ankles, or abdomen.
Have irregular heartbeats, palpitations, dizziness, or fainting spells.
Develop unexplained weight loss, numbness, tingling, or symptoms affecting multiple organs.
Have a family history of hereditary amyloidosis or are diagnosed with amyloidosis and develop heart-related symptoms.

High-risk groups:

Adults over 60 years of age
Individuals with hereditary transthyretin (ATTR) amyloidosis
People diagnosed with AL (light-chain) amyloidosis
Patients with unexplained heart failure or thickened heart muscle

Do not ignore persistent or worsening heart-related symptoms. Consult a Cardiologist for evaluation. Early diagnosis and treatment can help preserve heart function and improve long-term outcomes.

Find Cardiologists for Cardiac Amyloidosis Treatment Near You

How is Cardiac Amyloidosis Diagnosed?

Accurate and timely diagnosis of cardiac amyloidosis is vital for effective management. The diagnostic process typically involves a combination of clinical evaluation, laboratory testing, and imaging studies.

Diagnostic Techniques

Echocardiography: This imaging modality reveals characteristic features such as thickened ventricular walls and reduced diastolic function.
Cardiac Magnetic Resonance Imaging (MRI): MRI provides detailed images of the heart structure and can detect amyloid deposits through characteristic patterns.
Biopsy: A definitive diagnosis often requires a tissue biopsy, usually obtained from the abdominal fat pad, rectal mucosa, or directly from the heart muscle.
Blood and Urine Tests: These tests can detect abnormal proteins, aiding in the differentiation between AL and ATTR amyloidosis.

What are the Treatment Options for Cardiac Amyloidosis?

The management of cardiac amyloidosis involves addressing both the underlying cause and the cardiac manifestations. Treatment strategies may differ based on the type of amyloidosis and the extent of cardiac involvement.

Therapeutic Approaches

For AL Amyloidosis: The primary goal is to reduce the production of abnormal light chains. This can be achieved through chemotherapy, similar to the treatment of multiple myeloma, and autologous stem cell transplantation in eligible patients.
For ATTR Amyloidosis: Treatment focuses on stabilizing or reducing transthyretin production. Tafamidis is a medication approved for this purpose. Additionally, liver transplantation may be considered in hereditary cases, as the liver produces the majority of transthyretin.
Supportive Heart Failure Treatment: Standard heart failure therapies, including diuretics, beta-blockers, and ACE inhibitors, are used with caution, as their efficacy may be limited in amyloid-related heart failure.

Emerging Treatments

Ongoing research has introduced novel therapies targeting amyloid deposits directly. These include monoclonal antibodies designed to clear amyloid fibrils and gene-silencing therapies aimed at reducing amyloid precursor protein production.

Your health is everything - prioritize your well-being today.

Consult Cardiac Amyloidosis Doctors Today

What is the Prognosis for Cardiac Amyloidosis?

The prognosis of cardiac amyloidosis varies considerably, depending on the type and stage at diagnosis. AL amyloidosis, if untreated, can lead to rapid disease progression and poor outcomes. Conversely, advancements in ATTR amyloidosis treatments have significantly improved life expectancy and quality of life.

Regular follow-up with a multidisciplinary team, including cardiologists, hematologists, and genetic counselors, is crucial for optimizing patient outcomes.